Drugs / AFO-18
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02787109 | Jul 2016 → Jul 2017 | chlamydia trachomatis infectious disease | Statens Serum Institut | Completed | No outcome recorded |
| Phase 1 | NCT00922363 | Oct 2009 → Oct 2011 | tuberculosis | Statens Serum Institut | Completed | No outcome recorded |
| Phase 1 | NCT01141205 | Aug 2009 → Jun 2012 | AIDS | Statens Serum Institut | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01009762 Comparator | Sep 2009 → Mar 2012 | HIV infectious disease | Gitte Kronborg | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AFO-18 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01141205 ↗ |
| Known as | CAF01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00922363 ↗ |
| Modality | Other / unclassified | “new Liposomal Adjuvant System, CAF01” NCT00922363 ↗ |
| Route | Intramuscular | “intra muscularly (i.m.)” NCT01009762 ↗ |